Prestige Biologics Co., Ltd. (KOSDAQ:334970)

Prestige Biologics Balance Sheet

Financials in millions KRW. Fiscal year is July - June.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Dec 31, 2022
Cash & Equivalents	6,943	1,582	29,507	45,435	15,383
Short-Term Investments	-	-	-	-0	-
Cash & Short-Term Investments	6,943	1,582	29,507	45,435	15,383
Cash Growth	338.93%	-94.64%	-35.06%	195.36%	-58.17%
Accounts Receivable	3,191	438.43	389.19	1,074	40.75
Other Receivables	2,163	4,525	1,265	999.61	2,036
Receivables	5,354	4,963	1,654	2,073	2,077
Inventory	27,615	26,909	17,805	6,833	12,034
Prepaid Expenses	201.19	224.64	222.48	147.86	129.05
Other Current Assets	4,787	7,170	6,446	15,754	213.14
Total Current Assets	44,901	40,848	55,636	70,242	29,835
Property, Plant & Equipment	220,120	228,406	233,052	234,435	227,107
Other Intangible Assets	1,536	1,032	676.96	1,047	1,108
Other Long-Term Assets	-	0	50	28.82	28.82
Total Assets	266,557	270,286	289,414	305,753	258,079

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Dec 31, 2022
Accounts Payable	6,744	7,237	3,048	587.44	1,011
Accrued Expenses	700.2	504.58	6,636	3,149	1,612
Short-Term Debt	49,272	44,627	36,726	30,209	-
Current Portion of Long-Term Debt	30,245	14,156	10,824	12,914	10,604
Current Portion of Leases	12.77	12.17	66.17	39.68	98.57
Current Unearned Revenue	120.9	263.16	573.03	578.25	1,247
Other Current Liabilities	65,405	35,617	34,432	41,620	17,978
Total Current Liabilities	152,498	102,417	92,306	89,098	32,552
Long-Term Debt	21,777	32,666	125,414	116,846	107,900
Long-Term Leases	-	-	12.17	6.72	16.68
Long-Term Deferred Tax Liabilities	1,825	-	-	-	-
Other Long-Term Liabilities	-	-	-	-	0
Total Liabilities	176,101	135,083	217,732	205,950	140,468

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Dec 31, 2022
Common Stock	38,876	38,876	30,751	30,554	30,554
Additional Paid-In Capital	341,501	341,501	257,963	256,059	256,059
Retained Earnings	-297,127	-245,907	-218,437	-189,063	-171,084
Comprehensive Income & Other	7,205	732.73	1,406	2,253	2,082
Shareholders' Equity	90,455	135,203	71,682	99,803	117,611
Total Liabilities & Equity	266,557	270,286	289,414	305,753	258,079

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Dec 31, 2022
Total Debt	101,306	91,461	173,043	160,016	118,619
Net Cash (Debt)	-94,364	-89,879	-143,536	-114,581	-103,236
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-1214.09	-1220.44	-2343.11	-1953.28	-1994.89
Filing Date Shares Outstanding	77.64	77.75	61.5	61.11	61.11
Total Common Shares Outstanding	77.64	77.75	61.5	61.11	61.11
Working Capital	-107,597	-61,568	-36,670	-18,855	-2,716
Book Value Per Share	1165.10	1738.89	1165.54	1633.22	1924.65
Tangible Book Value	88,919	134,171	71,005	98,756	116,504
Tangible Book Value Per Share	1145.32	1725.61	1154.53	1616.08	1906.52
Land	18,863	10,565	10,565	10,565	10,565
Buildings	70,181	70,180	70,180	70,150	68,072
Machinery	74,183	59,390	56,143	37,728	37,566
Construction In Progress	17,181	95,463	90,441	126,395	117,130

Data Source: S&P Global Market Intelligence Last updated: Aug 29, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 4, 2026

Data Sources Report a data error